Alcobra Pharma, an emerging company focused on the development of new medications to help patients with cognitive disorders, has announced financial results for the fourth quarter and fiscal year ended December 31, 2014, and provided a business update. The company reported ( (Dollar) 0.50) EPS for the quarter, beating the Thomson Reuters consensus estimate of ( (Dollar) 0.57) by (Dollar) 0.07. They set a 'buy' rating and a (Dollar) 10.00 price target on the stock. Analysts at Zacks downgraded ...
Read More
No comments:
Post a Comment